Simultaneously, CXCL9 and CXCL10 have been shown to increase levels of tumor infiltrating CD8+ effector T cells and NK cells, minimize metastasis, and are correlated with improved responses to checkpoint blockade and adoptive cell transfer therapies (124, 125). This evidence concerns the gene CXCL9 and neoplasm.